Paving the way for diversity in clinical trials


Hala Borno, MD, Assistant Professor of Medicine, Department of Oncology and Hematology, University of California, San Francisco

Jimmy Friedman, Chief Medical Officer of America, Genentech.

Jennifer Jones-McMains, Ph.D., Director of Global Clinical Affairs, Abbott Pharmaceuticals.

Maria Shigog, Ph.D., Health Equality and Diversity Coordinator, Lazarex Cancer Foundation.

Andrea Denikov, Registered Nurse and Nurse Counselor, National Cancer Institute; Head of Clinical Trials Operations, National Cancer Institute National Clinical Trials Network.

Lola Fashoyin-Aje, MD, Deputy Department Director and Associate Director, Science and Policy for Addressing Inequalities, Center of Excellence for Oncology, FDA.

Keanna Ghazvini, spokesperson for Pfizer Pharmaceuticals.

Food and Drug Administration: “Drug Trial Snapshots: NINLARO.”

National Cancer Institute: “National Institutes of Health Policy and Guidance on Inclusion of Women and Minorities as Subjects in Clinical Research,” “Inclusion of Women and Minorities as Participants in Research on Human Subjects,” “Cancer Variation.” “ Background.”

Lazarks Cancer Foundation.

Genentech Biotechnology Company.

Abbott Laboratories: “Abbott announces the start of a trial to evaluate the new Espri Btk scaffold for absorbable drugs.”

Pfizer Pharmaceuticals.

American Cancer Society.

American Society of Clinical Oncology.

Contemporary clinical trials: “Does the COVID-19 outbreak indicate a broader need for an urgent transformation in cancer clinical trial research?”

New York timesClinical trials are moving from the laboratory to people’s homes.

Massey Cancer Center, Virginia Commonwealth University: “First Lady Jill Biden visits Massey to discuss disparities in cancer and community-based research.”

ProPublica: “Black patients miss promises of cancer medication.”